Clinical article · Acute care, Specialties, Surgery and trauma

Euglycaemic ketoacidosis with SGLT2 inhibitors: recognition and management

Written for
Hospital physicians, surgeons, anaesthetists and residents
Reading time
7 minutes
Published
Updated

Written by the Sana Health team for clinicians. It summarises published guidance, is not a guideline and has not been peer reviewed. Check current local protocols before acting.

Key points

  • Patients taking an SGLT2 inhibitor can develop diabetic ketoacidosis with a normal or only mildly raised glucose.
  • The 2024 international consensus defines DKA without requiring marked hyperglycaemia, which helps capture euglycaemic presentations.
  • Any unwell patient taking an SGLT2 inhibitor needs a blood gas and a blood beta-hydroxybutyrate, whatever the glucose.
  • Treatment follows the DKA protocol, but glucose-containing fluid is needed early so that insulin can continue until ketosis resolves.
  • Most cases are preventable: stop the drug during acute illness and before surgery, and restart only when eating and drinking normally.

Why the glucose misleads

SGLT2 inhibitors lower glucose by making the kidney excrete it. They also raise glucagon and increase the reabsorption of ketones by the renal tubule, which favours ketone production [3]. When insulin is relatively deficient, as in acute illness, fasting or after a reduction in insulin dose, ketoacidosis can develop while glucose stays near normal because it continues to be lost in the urine. The risk is small but real [4], and euglycaemic ketoacidosis has become more frequent as these drugs are used more widely for diabetes, heart failure and kidney disease [2].

Traditional definitions of DKA required a glucose above 250 mg/dL (13.9 mmol/L) [12]. The 2024 consensus from the ADA, EASD, JBDS, AACE and the Diabetes Technology Society instead requires a glucose of 11.1 mmol/L (200 mg/dL) or more or known diabetes, a blood beta-hydroxybutyrate of 3.0 mmol/L or more, and a pH below 7.3 or bicarbonate below 18 mmol/L [1]. A patient with known diabetes and ketoacidosis meets the definition whatever the glucose.

Who is at risk

  • Surgery and the perioperative period, especially with prolonged fasting [6].
  • Acute illness with vomiting, dehydration or reduced food intake.
  • Low-carbohydrate or ketogenic diets, and alcohol excess.
  • Recent reduction or omission of insulin, and insulin-deficient diabetes, including latent autoimmune diabetes and type 1 diabetes treated with an SGLT2 inhibitor.
  • Pregnancy, in which euglycaemic presentations are common: up to 35% of DKA cases in pregnancy have been reported to present with euglycaemia [9].

Recognition

The symptoms are those of DKA (nausea, vomiting, abdominal pain, malaise and breathlessness), but they are often attributed to gastroenteritis, postoperative ileus or a slow recovery. The test that matters is blood beta-hydroxybutyrate with a blood gas. Many laboratory and urine ketone tests are semiquantitative and do not measure beta-hydroxybutyrate, the predominant ketone, which can mislead [10].

FeatureClassic DKAEuglycaemic DKA on an SGLT2 inhibitor
GlucoseUsually markedly raisedNormal or mildly raised
Ketones and acidosisPresentPresent; may be severe
Urine glucosePositiveStrongly positive from the drug itself, so unhelpful
Common settingType 1 diabetes, missed insulin, infectionSurgery, fasting, acute illness, insulin reduction
Fluid needsSaline first, glucose added as glucose fallsGlucose-containing fluid needed early

Consider other causes of a raised anion gap acidosis alongside ketoacidosis: lactic acidosis, alcoholic or starvation ketoacidosis, toxic alcohols and kidney failure.

Management

Treatment follows the hospital DKA protocol, which in most countries now reflects the 2024 consensus [1], with one important change: because glucose is not high, glucose-containing fluid is needed early so that the insulin infusion can continue to switch off ketone production [2, 9].

  1. Stop the SGLT2 inhibitor.
  2. Resuscitate with intravenous fluid according to volume status.
  3. Check potassium before insulin; replace it according to the protocol, and do not start insulin while potassium is low.
  4. Start a fixed-rate intravenous insulin infusion by weight, commonly 0.1 units/kg/h in UK practice, with glucose-containing fluid alongside from the start or as soon as glucose falls to the protocol threshold.
  5. Monitor ketones, venous pH or bicarbonate, glucose and potassium regularly, and treat the precipitant.
  6. Continue until resolution: ketones below 0.6 mmol/L with a venous pH of 7.3 or more or bicarbonate of 18 mmol/L or more, then overlap subcutaneous insulin before stopping the infusion.

Glycosuria and the tendency to ketosis can persist for several days after the drug is stopped, so ketones should be rechecked if the patient becomes unwell again. Severe cases need critical care review.

A worked example

A patient with type 2 diabetes taking empagliflozin and metformin is nauseated and vomiting two days after a laparoscopic cholecystectomy, having eaten little since the operation. Glucose is 8.9 mmol/L, venous pH 7.18, bicarbonate 10 mmol/L and blood beta-hydroxybutyrate 5.4 mmol/L, with a raised anion gap.

Known diabetes, ketones above 3.0 mmol/L and a pH below 7.3 meet the consensus definition of DKA despite the near-normal glucose [1]. The plan is to stop empagliflozin and metformin, give fluid, check potassium, and start a fixed-rate insulin infusion with glucose-containing fluid from the outset, monitoring ketones and gas until resolution. The surgical team should look for a complication that may have reduced intake, and the diabetes team should advise on whether the SGLT2 inhibitor is restarted.

Prevention and the perioperative period

Most cases follow a predictable trigger. Patients should be taught sick-day rules: stop the SGLT2 inhibitor during an illness that reduces eating or drinking, and restart only when well. Expert panels have set out recommendations for prevention and early diagnosis [5].

Before surgery, the US FDA advises stopping SGLT2 inhibitors 3 to 4 days beforehand, but other multisociety recommendations vary on how long to withhold them and how to monitor [8]. UK multidisciplinary consensus statements also address them in the perioperative period [7, 11]. Whatever the protocol, the drug is restarted only when the patient is eating and drinking normally, and ketones are checked in any patient who is unwell after surgery.

Traps

  • Reassurance from a normal glucose in an unwell patient taking an SGLT2 inhibitor.
  • Relying on a urine ketone dipstick or a semiquantitative blood test.
  • Stopping or reducing the insulin infusion because glucose is normal, instead of adding glucose.
  • Labelling the presentation as gastroenteritis or ileus without a blood gas.
  • Restarting the drug before the patient is eating and drinking normally.
  • Missing insulin deficiency in a patient labelled as having type 2 diabetes.

How Sana Health helps

The Diabetes and Endocrine engine checks the diagnostic criteria for ketoacidosis without being misled by a normal glucose, and flags SGLT2 inhibitor use, pregnancy and fasting as reasons to suspect a euglycaemic presentation. Its plan is written out as a calculated regimen: fluids, a weight-based insulin infusion, potassium replacement checked before insulin, when to add glucose, the monitoring schedule, resolution criteria and the move to subcutaneous insulin. US product information for the SGLT2 inhibitor is attached from DailyMed, with guidelines and reviews from PubMed.

Questions

Why does DKA occur with a normal glucose on SGLT2 inhibitors?

The drug keeps removing glucose in the urine, so blood glucose stays low even when insulin is insufficient. Relative insulin deficiency, raised glucagon and reduced ketone excretion then allow ketoacidosis to develop.

How is euglycaemic DKA treated?

With the DKA protocol: fluids, potassium, and a fixed-rate insulin infusion, plus glucose-containing fluid from early on so the insulin can continue until ketones clear. The SGLT2 inhibitor is stopped and the precipitant treated.

Can SGLT2 inhibitors be restarted after an episode of ketoacidosis?

That is an individual decision for the diabetes team. Many patients do not restart; if the drug is restarted, it should only be once the patient is well, eating normally, on adequate insulin if needed, and taught sick-day rules.

References

  1. Hyperglycemic Crises in Adults With Diabetes: A Consensus Report (opens in a new tab)Diabetes Care, 2024
  2. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors (opens in a new tab)BMJ Open Diabetes Res Care, 2023
  3. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials (opens in a new tab)Diabetes Res Clin Pract, 2017
  4. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors (opens in a new tab)J Clin Endocrinol Metab, 2020
  5. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis (opens in a new tab)Clin Ther, 2016
  6. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review (opens in a new tab)Br J Anaesth, 2019
  7. Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement: A consensus statement from the Association of Anaesthetists, Association of British Clinical Diabetologists, British Obesity and Metabolic Surgery Society, Centre for Perioperative Care, Joint British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists, Society for Obesity and Bariatric Anaesthesia and UK Clinical Pharmacy Association (opens in a new tab)Anaesthesia, 2025
  8. Perioperative management of patients taking sodium-glucose cotransporter 2 inhibitors: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement (opens in a new tab)Br J Anaesth, 2026
  9. Diagnosis and Management of Euglycemic Diabetic Ketoacidosis in Pregnancy (opens in a new tab)Obstet Gynecol, 2026
  10. Controversies Around the Measurement of Blood Ketones to Diagnose and Manage Diabetic Ketoacidosis (opens in a new tab)Diabetes Care, 2022
  11. Peri-operative management of diabetes mellitus: a multidisciplinary consensus statement from the Association of Anaesthetists and the Joint British Diabetes Societies for Inpatient Care group (opens in a new tab)Anaesthesia, 2026
  12. Diabetic Ketoacidosis: Evaluation and Treatment (opens in a new tab)Am Fam Physician, 2024